Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332) | Publicación